BridgeBio Pharma, Inc. (BBIO)
76.50
-0.07
(-0.09%)
USD |
NASDAQ |
Sep 02, 16:00
76.55
+0.05
(+0.07%)
After-Hours: 05:07
BridgeBio Pharma Research and Development Expense (Annual) : 451.95M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 451.95M |
| December 31, 2024 | 506.46M |
| December 31, 2023 | 455.71M |
| December 31, 2022 | 399.46M |
| December 31, 2021 | 451.02M |
| Date | Value |
|---|---|
| December 31, 2020 | 337.05M |
| December 31, 2019 | 209.95M |
| December 31, 2018 | 140.07M |
| December 31, 2017 | 30.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Ionis Pharmaceuticals, Inc. | 913.18M |
| Pfizer Inc. | 10.25B |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| BioMarin Pharmaceutical, Inc. | 700.97M |